Applied Molecular Transport to Present at Virtual Jefferies London Healthcare Conference

Rhea-AI Summary

Applied Molecular Transport Inc. (Nasdaq: AMTI) announced that Dr. Bittoo Kanwar and Liz Bhatt will participate in a fireside chat at the Virtual Jefferies London Healthcare Conference on November 18, 2021, at 8:00 a.m. GMT. The discussion will focus on AMT's innovative approach to developing oral biologic product candidates targeting autoimmune and metabolic diseases. A recorded version of the chat will be available on AMT's Events page for 30 days post-event. AMT utilizes a proprietary platform for efficient therapeutic transport across the intestinal barrier, setting it apart in the biopharmaceutical landscape.

SOUTH SAN FRANCISCO, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that Bittoo Kanwar, M.D., chief medical officer, and Liz Bhatt, chief business and strategy officer, will participate in a fireside chat during the Virtual Jefferies London Healthcare Conference on Thursday, November 18, 2021 at 8:00 a.m. GMT.

To access the archived recording of the fireside chat, please visit the Events page of the Applied Molecular Transport website at https://ir.appliedmt.com/news-events/events. The archived replay will be available for 30 days following the event.

About Applied Molecular Transport Inc.
Applied Molecular Transport Inc. is a clinical-stage biopharmaceutical company leveraging its proprietary technology platform to design and develop a pipeline of novel oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. AMT’s proprietary technology platform allows it to exploit existing natural cellular trafficking pathways to facilitate the active transport of diverse therapeutic modalities across the intestinal epithelial (IE) barrier. Active transport is an efficient mechanism that uses the cell’s own machinery to transport materials across the IE barrier. AMT believes that its ability to exploit this mechanism is a key differentiator of its approach. AMT is developing additional oral biologic product candidates in patient-friendly oral forms that are designed to either target local gastrointestinal tissue or enter systemic circulation to precisely address the relevant biology of a disease.

AMT’s headquarters, internal GMP manufacturing and lab facilities are located in South San Francisco, CA. For additional information on AMT, please visit www.appliedmt.com.

Investor Relations Contact:
Andrew Chang
Head, Investor Relations & Corporate Communications
achang@appliedmt.com

Media Contacts:
Alexandra Santos
Wheelhouse Life Science Advisors
asantos@wheelhouselsa.com

Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com

FAQ

What event will AMTI participate in on November 18, 2021?

AMTI will participate in a fireside chat during the Virtual Jefferies London Healthcare Conference.

Who from AMTI will speak at the Jefferies London Healthcare Conference?

Dr. Bittoo Kanwar and Liz Bhatt will represent AMTI at the conference.

Where can I find the recorded fireside chat from AMTI?

The recorded chat will be available on AMTI's Events page for 30 days after the event.

What is the focus of AMTI's product development?

AMTI focuses on developing oral biologic products for autoimmune, inflammatory, and metabolic diseases.

What differentiates AMTI's technology platform?

AMTI's platform enables active transport of therapeutics across the intestinal barrier, enhancing delivery efficiency.